Some experts say oral versions of popular weight-loss drugs such as Wegovy could offer people more flexibility and ...

Let's look at why this news could be a game-changer for Eli Lilly and its stock.

People with type 2 diabetes taking the highest dose of Eli Lilly’s experimental drug orfoglipron lowered their blood sugar and lost 16 pounds on average after 40 weeks.

Drugmaker Eli Lilly said Thursday that an experimental pill form of popular GLP-1 medications helped people with type 2 ...

GLP-1 medication use spiked, as well ... Half of the participants got a weekly shot of semaglutide, the drug in Ozempic and ...

Former Playboy star Kendra Wilkinson revealed that she started taking a weight-loss drug but threw the medication away after ...

Eli Lilly’s shares shot up 11% pre-market on Thursday after orforglipron became the first small-molecule GLP-1 drug to ace a ...

Drugmaker Eli Lilly (LLY 14.56%) hasn't been exempt from the recent market pullback, but its stock shot higher following the announcement that its newest GLP-1 drug had successfully completed the ...

Last quarter alone, its two leading GLP-1 drugs, Mounjaro and Zepbound, generated a combined $5.4 billion in revenue. Zepbound revenue soared from $175.8 million to $1.9 billion, while Mounjaro ...